NCT04354727View on ClinicalTrials.gov

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 15, 2020

Primary Completion Date

December 15, 2022

Study Completion Date

June 15, 2023

Conditions
Myelofibrosis
Interventions
DRUG

APG-1252

infusion once weekly

DRUG

Ruxolitinib

taken orally twice a day

Trial Locations (2)

77030

University of Texas MD Anderson Cancer Center, Houston

85234

Banner MD Anderson Cancer Center, Gilbert

Sponsors
All Listed Sponsors
lead

Ascentage Pharma Group Inc.

INDUSTRY